March 1, 2024 07:04 AM EST
People
Peer Review

Pfiz­er names a VC leader in year of re­set; For­mer Ax­cel­la CEO moves on af­ter com­pa­ny shut­down

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ A spokesper­son for Pfiz­er tells Peer Re­view that Michael Diem has joined the phar­ma gi­ant as head of ven­ture cap­i­tal & eq­ui­ty in­vest­ments. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times